Open-Label Extension Study of 23 mg Donepezil SR in Patients With Moderate to Severe Alzheimer's Disease
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of long-term administration
of 23 mg donepezil sustained release (SR) in patients with moderate to severe Alzheimer's
disease. Patients who complete study E2020-G000-326 with no ongoing serious adverse events
(SAEs) and no serious adverse drug reactions will be eligible to enter the open-label
extension study.